Drug-resistant TB: latest news

Drug-resistant TB features

Drug-resistant TB news from aidsmap

  • MDR-TB numbers could keep growing despite improved treatment

    Up to one-in-three tuberculosis cases in Russia could be multidrug resistant by 2040, and one-in-eight in India, unless more is done to stop the person-to-person spread of drug-resistant TB and sub-optimal treatment, a modelling study published ...

    11 May 2017 | Keith Alcorn
  • Three-drug regimen beats XDR-TB in first trial

    A regimen of three oral drugs given for six months was enough to clear extensively drug-resistant tuberculosis (XDR-TB) in 29 of the first 31 people to have completed the treatment course, Dr Francesca Conradie of Sizwe Tropical Disease Hospital, ...

    17 February 2017 | Keith Alcorn
  • Shortened regimen for MDR-TB shows good results for children

    The use of the shortened 9-month treatment regimen for multidrug-resistant tuberculosis (MDR-TB), known as the ‘Bangladesh regimen’ has shown to be successful in 83% of children and adolescents diagnosed with rifampicin-resistant (RR) TB. The findings were presented at TB2016, a ...

    18 July 2016 | Lesley Odendal
  • South Africa’s XDR-TB epidemic is due to transmission rather than evolution of resistant strains

    A study in KwaZulu-Natal, South Africa, evaluating the social networks as well as clinical and genotypic data from individuals with extensively drug resistant tuberculosis (XDR-TB) has concluded that transmission – in both hospitals and households – has been the primary ...

    04 March 2016 | Theo Smart
  • Empirical TB treatment comes up short again

    A South African trial has found that a strategy allowing primary care nurses to quickly provide empirical tuberculosis (TB) treatment for newly diagnosed people with advanced HIV disease at very high risk of, but without confirmed, TB did not ...

    26 February 2016 | Theo Smart
  • MDR-TB treatment: Six drugs better than five

    A regimen containing six drugs was more likely to cure multi-drug resistant tuberculosis (MDR-TB) than a regimen containing five drugs, a nine-country observational study has shown. The study also found that each active drug in the ...

    13 January 2016 | Keith Alcorn
  • Xpert MTB/RIF testing has reduced MDR-TB treatment delays in South Africa

    Although the introduction of the Xpert MTB/RIF test for TB and drug-resistant TB has improved the time from clinic presentation to second-line treatment in South Africa since 2011, improved access to treatment and a reduction in delays of treatment ...

    07 January 2016 | Lesley Odendal
  • One in eight children with confirmed TB have drug-resistant TB in Cape Town

    One in eight children with confirmed TB have drug-resistant TB in Cape Town, South Africa, according to a surveillance study of childhood TB drug-resistance, presented by Professor Simon Schaaf at the 46th Union World Conference on Lung Health held ...

    05 January 2016 | Lesley Odendal
  • Death during MDR-TB treatment more likely in people with HIV and underweight or most drug-resistant patients

    People living with HIV, those who are underweight and those with more extensive drug resistance are more likely to die during treatment for multi-drug resistant tuberculosis (MDR-TB), a nine-country study has found. The findings were presented at the 46th ...

    10 December 2015 | Keith Alcorn
  • 9-month MDR-TB regimen cures 82% in African study

    A 9-month standardised treatment regimen for multi-drug resistant tuberculosis (MDR-TB) cured 82% of people recruited to an observational study in Francophone Africa, the 46th Union World Conference on Lung Health heard on Saturday in Cape Town. The regimen showed similar ...

    07 December 2015 | Keith Alcorn
More news

Drug-resistant TB news selected from other sources

  • Could a New Universal Tuberculosis Regimen Help End the TB Pandemic?

    As tuberculosis (TB) is the world's most lethal infectious disease, there is an urgent need to improve the treatment of this bacterial infection. One approach under consideration is the institution of a universal or “pan-TB” regimen comprising new agents capable of treating multidrug-resistant (MDR) and even extensively drug-resistant (XDR) TB.

    29 May 2018 | Infectious Disease Advisor
  • Study finds more than 80 percent of patients needing WHO recommended last resort treatment for drug-resistant TB not getting it

    Roughly four years after the World Health Organization recommended that the newest drugs against tuberculosis be made available to patients for whom they represented a last resort, fewer than a fifth of patients needing them have received them, according to a report in the International Journal of Tuberculosis and Lung Disease.

    06 April 2018 | Science Speaks
  • WHO issues recommendations on management of isoniazid-resistant tuberculosis

    Within the context of an ongoing extensive review of evidence on treatment of drug-resistant (TB) taking place in 2018, the World Health Organization (WHO) has issued a Supplement to its current drug-resistant TB treatment guidelines, providing recommendations for the management of isoniazid-resistant TB. These will be incorporated into the Consolidated Guidelines for Treatment and Care of Drug-resistant TB envisaged by WHO later in 2018.

    22 March 2018 | World Health Organization
  • J&J, Macleods in talks for licence deal of tuberculosis drug

    Mumbai-based Macleods Pharmaceuticals and US drug giant Johnson & Johnson(J&J) are in talks for a voluntary licence deal for the tuberculosis drug Bedaquiline, EThas learnt.

    13 March 2018 | Economic Times
  • How both sides in Ukraine's war are losing the HIV battle

    Displacement, aid delivery issues, and different strategies are all feeding a raging epidemic.

    16 February 2018 | IRINnews.org
  • Promising MSF Research Highlights Immense Benefits, Need for Expanded Use of DR-TB Drug Combination

    New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease. These findings encourage the wider use of these medicines in combination for DR-TB patients worldwide.

    14 February 2018 | MSF press release
  • TB treatment outcomes good for multidrug-resistant TB/HIV co-infected patients who start ART

    Treatment of multidrug-resistant tuberculosis (TB) has comparable efficacy and survival rates in patients infected with HIV and not uninfected with HIV when patients with HIV are given antiretroviral therapy.

    01 February 2018 | Medical Brief
  • A global study reveals new TB mutations that could transform tests for drug resistance

    Resistance to the antibiotics used to treat TB is caused by mutations in the bacterial genome and new rapid molecular (DNA) tests are being developed, but detecting resistance relies on knowing which mutations to look for…. and there are potentially hundreds of mutations.

    24 January 2018 | London School of Hygiene and Tropical Medicine
  • People still being denied improved treatment for multidrug-resistant TB

    People with multidrug-resistant tuberculosis (MDR-TB) are still not receiving two newer TB drugs, bedaquiline and delamanid, which have been available for more than four years and have shown improved cure rates for the disease, deplored Médecins Sans Frontières (MSF) at the 48th Union World Conference on Lung Health in Guadalajara, Mexico, where the global TB community is meeting.

    16 October 2017 | Médecins Sans Frontières (MSF) International
  • STREAM clinical trial results provide vital insight into nine-month treatment regimen for multidrug-resistant tuberculosis

    Preliminary results - released today at the 48th Union Conference on Lung Health - from Stage 1 of the STREAM randomised clinical trial show that the nine-month treatment regimen being tested achieved favourable outcomes in almost 80 percent of those treated. The results suggest the nine-month regimen is very close to the effectiveness of the 20-24 month regimen recommended in the 2011 WHO guidelines, when both regimens are given under trial conditions.

    16 October 2017 | 48th Union World Conference on Lung Health
More news
Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.